We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
During their stay in hospital, around 7-10% of patients attract unexpected infections. In some cases, this is caused by unclean complex surgical tools. Aspetium have developed ultrasonic washers (dubbed "uSonic") to thoroughly decontaminate expensive surgical instruments, which can be safely reused to potentially prevent easily avoidable infections.
days to go: Expired investment: £151,167
AgPlus has created a diagnostic platform for detecting human diseases and delivering laboratory instrument results instantly, whilst keeping in mind the business requirements and unmet requirements. The company works in collaboration with leading diagnostics companies to improve and share products quickly and globally. It aims is to become known as a leader in Point of Care diagnosis.
days to go: Expired investment: £65,004
Using AI technology to help the elderly feel safer and more comfortable in their homes. miicare has developed wearable devices and wireless sensors to monitor body vitals. If any irregularity occurs a call will be placed to a family member, a social worker, or a 24/7 professional telecare service. This increases support for the elderly and peace of mind knowing an emergency can be easily and quickly addressed. All data is secured using blockchain encryption.
days to go: Expired investment: £321,920
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £270,543
Aerobit is a smart inhaler, a tool for tracking medication use that records each time inhalers are taken and comes in a variety of cool toy designs. Built in sensors can even tell if the inhaler has been shaken correctly. 
days to go: Expired investment: £116,960
United Medicine have created a platform where experience, knowledge and opinion of their medical users is used to provide a global consensus and allows the good evidence to be separated from the bad.   
days to go: Expired investment: £152,000
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go: Expired investment: Withheld
Regenerative Medical Group provides a remedy for Wound Healing and Erectile Dysfunction (ED) by using non-invasive technology. It partners with clinics to render the service such as reception, treatment rooms and nurses. In addition to the Erectile Dysfunction (ED) market, it has identified wound healing as a new market. Currently, it is working with an experienced NHS/NICE validation team to show its value as a treatment modality. RMG reached revenues of £400k, -56k EBITDA in the financial year 2017, and is operational in 5 clinics.
days to go: Expired investment: £67,740
Care Oncology Clinic is changing the face of cancer treatment by developing combinations of medicines to be taken alongside existing treatments such as radiotherapy, chemotherapy, hormone therapy and immunotherapy. 
days to go: Expired investment: £145,038
BiVictriX Therapeutics is a pharmaceutical company that are developing ADC's (Antibody Drug Conjugates) in the field of Oncology. They have invented a strategy that improves ADC selectivity towards cancer cells.
days to go: Expired investment: £451,506
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph